Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
-0.93 (-1.16%)
4:11:40 PM EDT: $78.79 -0.11 (-0.14%)

Moderna Announces Updates On Respiratory Syncytial Virus Vaccine Program

Published: 10/08/2020 11:06 GMT
Merck & Co Inc (MRK) - Moderna Announces Updates on Respiratory Syncytial Virus (rsv) Vaccine Program.
Moderna Inc - Moderna Regains Rights to Adult Rsv Vaccine Program From Merck.
Moderna Inc - Start of Phase 1 Dosing for Mrna-1345, Moderna's Vaccine Candidate Against Rsv.
Moderna Inc - Moderna Has Consolidated All Rights to Its Prophylactic Vaccines Portfolio.
Moderna Inc - Merck Decided to Focus Its Efforts on Rsv Infections Through Its Antibody Program That is Currently in Phase 2 Development.
Moderna - Will Have Right to Also Advance Rsv Vaccines in Adults, Either Alone Or in Combination With Other Respiratory Virus Vaccines.
Moderna Inc - Under Terms of Agreement, Merck Will Complete Phase 1 Study and Transition Program to Moderna.
Moderna Inc - Moderna and Merck Will Continue Their Ongoing Collaboration in Cancer Vaccines.